Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma · Metastatic Gastric Cancer · Gastroesophageal Junction Cancer · Esophageal Adenocarcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 840 (planned)
- Started
- May 14, 2026
- Main results expected
- Jul 22, 2031
- Fully finished
- Jul 21, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Measured over: Approximately 4 years
Phase 2: Number of participants with treatment-emergent adverse events
Measured over: Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Measured over: Approximately 4 years
Phase 3: Overall Survival (OS)
Measured over: Approximately 4 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07392892 · record last updated 2026-10-13 · checked 2026-11-09 15:42 UTC